Sarepta Seeks Full FDA Approval With Re-Analyzed Trial Data

Sarepta Re-Analyzes Trial Data to Reach P=0.050 Significance

Sarepta Therapeutics will file for full U.S. Food and Drug Administration (FDA) approval for its Duchenne muscular dystrophy (DMD) drugs, Amondys 45 and Vyondys 53, by the end of April. The company is attempting to convert the therapies' accelerated approvals, granted in 2021 and 2019 respectively, into traditional approvals. The move comes after the pivotal ESSENCE confirmatory study failed to meet its primary endpoint of improving motor function, a significant setback announced last year.

To support the new application, Sarepta re-analyzed the ESSENCE data. After excluding 23 participants, or about 10% of the study population, whose data was reportedly impacted by the COVID-19 pandemic, the results reached borderline statistical significance (P=0.050). This is a marked change from the original analysis of the full 225-patient study, which was not statistically significant (P=0.309). While the FDA has agreed to review the filing, the adequacy of this revised data remains a key question for regulators.

Real-World Evidence from 1,800 Patients Bolsters Case

Sarepta is strengthening its application with a substantial body of real-world evidence collected from over 1,800 patients who have used the therapies commercially. This data points to significant long-term benefits not captured in the formal trial. Specifically, evidence suggests treatment with Vyondys 53 is associated with a 7.5-year delay in the need for nighttime ventilation, while Amondys 45 demonstrated a statistically significant slowing of lung function decline.

Across its portfolio of similar drugs, Sarepta claims real-world data shows a delay in the loss of ambulation of three to four years and a multi-year survival benefit. This strategy of supplementing trial results with real-world outcomes in rare diseases is central to the company's argument.

In rare diseases like Duchenne, where progression varies widely and meaningful functional changes unfold over years—not months—incorporating real-world data alongside clinical findings can help us better understand long-term outcomes.

— Louise Rodino‑Klapac, President of Research & Development at Sarepta.

A High-Stakes Bet for a Company in Transition

The FDA's decision carries significant weight for Sarepta. A full approval would secure future revenue for Amondys 45 and Vyondys 53 and validate the company's development strategy. Conversely, a rejection could force the drugs to be withdrawn from the market, representing a major financial and strategic blow. This regulatory push occurs during a difficult period for the company, which has faced weakening sales for its other DMD gene therapy, Elevidys, and is managing the planned departure of CEO Doug Ingram at the end of the year.